The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Venetoclax plus ibrutinib delivers durable remissions after BTK inhibitor resistance in CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses long-term follow-up from a Phase II study (NCT03513562) evaluating venetoclax added to ibrutinib in patients with chronic lymphocytic leukemia (CLL) who developed BTK inhibitor resistance mutations. Dr Rogers highlights the durability of responses achieved with this approach, including deep remissions, measurable residual disease (MRD) negativity, and prolonged treatment-free intervals for many patients. She also explores how these findings support ongoing efforts to develop fixed-duration combination strategies in the post-BTK inhibitor setting. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
